Skip to main content

Treatment Clinical Trials for Myelodysplastic/Myeloproliferative Disease

Review the myelodysplastic/myeloproliferative disease treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 56

Eltrombopag for the Treatment of Relapsed or Refractory Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-0 with TET2 Mutations
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Olutasidenib Combined with Co-targeted Therapy for the Treatment of Myeloid Cell Cancers in Patients with IDH1 and Co-signaling Gene Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Standard-of-Care Reduced-Intensity Conditioning with Total Body Irradiation for the Treatment of Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Personalized NK Cell Therapy after Chemotherapy and Cord Blood Transplant in Treating Patients with Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy and Cord Blood Transplant in Children and Young Adults with Blood Cancers or Non-malignant Disorders
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Pacritinib in Combination with Azacitidine for the Treatment of Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm with FLT3 or CBL Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Axatilimab in Combination with Ruxolitinib for the Treatment of Myelofibrosis and Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients with Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Genetically Engineered Cells (TGFBR2 KO CAR27/IL-15 NK cells) for the Treatment of Relapsed or Refractory Myeloid Malignancies
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy (Decitabine in Combination with FLAG-Ida) and Total-Body Irradiation followed by Donor Stem Cell Transplant for the Treatment of Adults with Myeloid Malignancies at High Risk of Relapse
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Combination Chemotherapy (FLAG-Ida) with Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
CPX-351 With or Without Venetoclax in Treating Patients with Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Neoplasms
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Infusion of Conventional and Regulatory T-Cells for the Treatment of Patients with Hematologic Malignancies Undergoing Reduced Intensity Donor Stem Cell Transplant
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Status: Active
Location: 5 locations
HA-1 T TCR T cell Immunotherapy for the Treatment of Patients with Relapsed or Refractory Acute Leukemia after Donor Stem Cell Transplant
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Adding Hyperbaric Oxygen Therapy to Allogeneic Stem Cell Transplant for Treating Hematologic Cancers
Status: Active
Location: University of Rochester, Rochester, New York
Azacitidine and Decitabine for the Treatment of Myelodysplastic Syndrome or Other Related Cancers
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Status: Active
Location: See ClinicalTrials.gov
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Status: Active
Location: See ClinicalTrials.gov